Clinical phase I data on Orion Corporation’s ODM-208, a first-in-class oral, non-steroidal and selective inhibitor of CYP11A1, the first and rate-limiting enzyme of steroid biosynthesis, were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium.
February 18, 2022
· 3 min read